0000874015-23-000093.txt : 20230207 0000874015-23-000093.hdr.sgml : 20230207 20230207173655 ACCESSION NUMBER: 0000874015-23-000093 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230203 FILED AS OF DATE: 20230207 DATE AS OF CHANGE: 20230207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Monia Brett P CENTRAL INDEX KEY: 0001537529 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 23596262 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT STREET 2: C/O IONIS PHARMACEUTICALS, INC. CITY: CARLSBAD STATE: CA ZIP: 92010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330336973 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2023-02-03 0 0000874015 IONIS PHARMACEUTICALS INC IONS 0001537529 Monia Brett P 2855 GAZELLE COURT CARLSBAD CA 92010 1 1 0 0 Chief Executive Officer Common Stock 2023-02-03 4 A 0 6511 0.0 A 127374 D Common Stock 2023-02-03 4 A 0 17210 0.0 A 144584 D Common Stock 2023-02-03 4 A 0 25372 0.0 A 169956 D Common Stock 2023-02-06 4 S 0 24651 40.6942 D 145305 D Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the final performance period of the grant to the reporting person reported on January 17, 2020. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 100% of target shares and a true-up of 72.24% of target shares pursuant to the alternative calculation. Since this PRSU award paid out less than 100% of target for tranche 1 and tranche 2 of such PRSU award, the alternative calculation applies, resulting in an additional payout of 1,146 shares under tranche 1 and 1,586 shares under tranche 2, yielding in the aggregate a total tranche 3 payout of 6,511 shares, or 172.24% of target Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the second performance period of the grant to the reporting person reported on January 20, 2021. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 100% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal. Represents shares earned upon the vesting of performance-based restricted stock units ("PRSUs") for the first performance period of the grant to the reporting person reported on January 19, 2022. The Compensation Committee certified achievement of the pre-established performance goal based on the Issuer's relative total shareholder return as compared to a peer group of companies at a level resulting in a vest of 150% of target shares. As reported at grant, the PRSUs could result in a payout of 0% to 150% based on actual achievement of the goal. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.37 to $40.95 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4. By: Patrick R. O'Neil, attorney-in-fact For: Brett P. Monia 2023-02-07